RC
ESPR

RegentAtlantic Capital’s Esperion Therapeutics ESPR Stock Holding History

RegentAtlantic Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,353
Closed -$200K – 435
2019
Q4 		$200K Buy
+3,353
New +$151K 0.01% 449

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

RegentAtlantic Capital's ESPR Position: Q1 2020 in Review

RegentAtlantic Capital sold out of Esperion Therapeutics (ESPR) in Q1 2020, closing a stake of 3,353 shares — an estimated $200K sold.

RegentAtlantic Capital first reported a position in ESPR in Q4 2019 and held it in 1 quarter. The position peaked at $200K in Q4 2019. 165 funds tracked by Wall St. Rank hold ESPR as of Q1 2020.

  • RegentAtlantic Capital reported no remaining Esperion Therapeutics position as of Q1 2020 after selling out during the quarter.
  • RegentAtlantic Capital sold 3,353 Esperion Therapeutics shares in Q1 2020, an estimated $200K.
  • RegentAtlantic Capital first reported a position in Esperion Therapeutics in Q4 2019 and held it in 1 quarter.
  • RegentAtlantic Capital's Esperion Therapeutics position peaked at $200K in Q4 2019.
  • 165 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2020.

Based on RegentAtlantic Capital's 13F filing for Q1 2020, filed 14 May 2020.